Skip to main content
. 2015 May;7(3):153–169. doi: 10.1177/1758834015572343

Figure 2.

Figure 2.

Proportion of patients (%) with graphical overall survival (OS) superiority (green), uncertain difference (orange) and absence of superiority (red) of cetuximab over bevacizumab in the AIO FIRE-3 study (A), in the CALGB/SWOG 80405 study (B), and estimation (mean) from both (C).